195833-59-1

Upstream product

• 139-02-6 sodium phenoxide 
• 63700-05-0 1,2;5,6-dianhydro-3,4-O-isopropylidene-D-mannitol 
• 71-43-2 benzene 
• 108-95-2 phenol 

Downstream Products

• 911441-31-1 O³,O⁴-isopropylidene-O¹,O⁶-diphenyl-O²,O⁵-bis-(toluene-4-sulfonyl)-D-mannitol 
• 50467-61-3 O¹,O⁶-diphenyl-D-mannitol 
• 211993-82-7 2,5-diazido-2,5-dideoxy-3,4-O-isopropylidene-1,6-di-O-phenyl-L-iditol 
• 1420479-83-9 C₂₃H₃₀O₁₀S₂ 
• 1420479-31-7 (3aS,4S,6S,6aS)-2,2-dimethyl-4,6-bis(phenoxymethyl)tetrahydroselenopheno[3,4-d][1,3]-dioxole 

Relevant academic research and scientific papers

C2-symmetric cyclic selenium-catalyzed enantioselective bromoaminocyclization

A catalytic asymmetric bromocyclization of trisubstituted olefinic amides that uses a C2-symmetric mannitol-derived cyclic selenium catalyst and a stoichiometric amount of N-bromophthalimide is reported. The resulting enantioenriched pyrrolidine products, which contain two stereogenic centers, can undergo rearrangement to yield 2,3-disubstituted piperidines with excellent diastereoselectivity and enantiospecificity.

1,2,5,6-Tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors

The synthesis and structure-activity relationships of HIV protease inhibitors derived from carbohydrate alditols are discussed. We disclose a new series of 1,2,5,6-tetra-O-alkyl-D-mannitol exhibiting sub-micromolar activity against HIV-protease. This seri

New potent C2-symmetric malaria plasmepsin I and II inhibitors.

A series of malaria plasmepsin (Plm) I and II inhibitors containing a C(2)-symmetric core structure have been synthesised and tested for protease inhibition activity. These compounds can be prepared using a straightforward synthesis involving a phenol nuc

D-mannitol derivatives as HIV aspartyl protease inhibitors

A D-mannitol derivative selected from the group consisting of a compound of formula pharmaceutically acceptable derivatives thereof and where applicable or appropriate pharmaceutically acceptable salts thereof, wherein R1, R2, R3and R4are the same or different and may each independently be selected from among alkyl and aryl (i.e. aromatic including aromatic like) groups. The D-mannitol derivatives may be used as HIV aspartyl protease inhibitors.

HIV-1 protease inhibitors based on acyclic carbohydrates

A series of acyclic C2-symmetric HIV protease inhibitors readily accessible from D-mannitol have been developed. Several of the compounds synthesized showed significant in vitro activity against HIV-1 protease.

Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities

Ten C2-symmetric cyclic urea and sulfamide derivatives have been synthesized from L-mannonic γ-lactone and D-mannitol. The results of experimental measurement of their inhibitory potencies against HIV-1 protease were compared to calculated free